Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer
Doshi J, Li P, Geng Z, Lei X, Pettit A, Armstrong K, Huntington S, Lin J. Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer. Blood 2024, 144: 786-786. DOI: 10.1182/blood-2024-203410.Peer-Reviewed Original ResearchInsurance typeBlood cancerMedicare patientsCommercial insuranceStep therapyFormulary coverageNationwide sample of patientsPrior authorizationTreatment plan changesDelayed treatment initiationMonths pre-indexOdds of rejectionLonger treatment durationLife-extending therapyReal-world studyOral anticancer medicationsSample of patientsBlood cancer patientsPatient ageClinical characteristicsTreatment initiationReal-world analysisBrand-nameRetrospective analysisPre-index